Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-5933 + Conteltinib in KRAS G12C-mutated solid tumors
NCT06970132Phase 2Not yet recruiting
- Sponsor
- Shouyao Holdings
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SY-5933, conteltinib in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC), sponsored by Shouyao Holdings. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
SY-5933conteltinib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06970132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970132.